Prelude Capital Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Prelude Capital Management’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,800	Closed	-$4K	–	1930
2017 Q3	$4K	Buy	+2,800	New	+$3.98K	﹤0.01%	1535
2016 Q1	–	Sell	-913	Closed	-$34K	–	1694
2015 Q4	$34K	Hold	913	–	–	0.01%	1113
2015 Q3	$44K	Buy	913 +775	+562%	+$54.1K	0.01%	1098
2015 Q2	$9K	Buy	+138	New	+$6.39K	﹤0.01%	1582

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Prelude Capital Management's ANTH Position: Q4 2017 in Review

Prelude Capital Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 2,800 shares — an estimated $4K sold.

Prelude Capital Management first reported a position in ANTH in Q2 2015 and held it in 4 quarters. The position peaked at $44K in Q3 2015. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

Prelude Capital Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 2,800 Anthera Pharmaceuticals, Inc. shares in Q4 2017, an estimated $4K.
Prelude Capital Management first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 4 quarters.
Prelude Capital Management's Anthera Pharmaceuticals, Inc. position peaked at $44K in Q3 2015.
37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.